Business
Enzolytics Announces the Filing of Updated NIH Grant Applications Incorporating Newly Identified Conserved Epitopes on Both the HIV-1 and SARS-CoV-2 Viruses; Other Corporate Updates
Enzolytics Announces the Filing of Updated NIH Grant Applications Incorporating Newly Identified Conserved Epitopes on Both the HIV-1 and SARS-CoV-2 Viruses; Other Corporate Updates.
About this update from Enzolytics Inc.
[{"type":"text","content":"COLLEGE STATION, TX / ACCESSWIRE / March 22, 2021 / Enzolytics, Inc. (OTC PINK:ENZC or the "Company") today announced it has filed NIH grant applications seeking funding for its production of monoclonal antibodies targeting the identified conversed epitope sites on both the HIV-1 and the SARS-CoV-2 viruses. Using its recent discovery of conserved sites on both viruses, the Company has filed updated NIH grant applications for funding for the production of monoclonal antibodies against these conserved sites on both viruses.In the case of the HIV viruses, 8 conserved sites on the HIV-1 virus, some with over 98% conserved sequences, have been identified using Artificial Intelligence to analysis over 87,336 HIV isolates now known. In the case of the Coronavirus, 11 conserved sites have been identified, with conserved sequences of from 97.68% to 99.28%. Patent applications have been filed covering both discoveries.The identification of these conserved sites on both viruses was accomplished using artificial intelligence techniques analyzing the 87,336 HIV isolates and 50,512 isolates on the Coronavirus.Using these new discoveries, the Company has bolstered its applications to the NIH seeking funding based on these additional discoveries. By renewing its applications with these significant additional discoveries, the prospect of grant funding is increased.These revised applications incorporate the focus on the capability to produce multiple (a "cocktail" of) monoclonal antibodies for therapeutic treatment. While the Company sees value in pursuing NIH grant funding, the progress of the Company is not in any way affected or delayed by awaiting the review of such applications. Preparing such applications allows the Company to marshal its technology in a detailed confidential technical presentation that can be used in discussing our technology with potential biotech partners.The December 31, 2021 year end OTC report for the Company is expected to be filed before the March 31, 2021 deadline. The Audits of the year ends December 31,2021 and 2020, that the PCAOB auditors were engaged to perform on January 31, 2020, along with the OTCQB application will be filed upon completion of the audits. No additional shares of the Company's common stock have been issued since October 15, 2020.Additionally, the Company has entered n...